Infectious complications of bispecific antibody therapy in patients with multiple myeloma.
作者信息
Sim Beatrice Z, Longhitano Anthony, Er Jeremy, Harrison Simon J, Slavin Monica A, Teh Benjamin W
机构信息
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.
National Centre for Infections in Cancer, Parkville, VIC, Australia.
出版信息
Blood Cancer J. 2023 Mar 10;13(1):34. doi: 10.1038/s41408-023-00808-8.
Abstract
摘要
相似文献
1
Infectious complications of bispecific antibody therapy in patients with multiple myeloma.多发性骨髓瘤患者双特异性抗体治疗的感染并发症
Blood Cancer J. 2023 Mar 10;13(1):34. doi: 10.1038/s41408-023-00808-8.
2
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.针对多发性骨髓瘤治疗的靶向 BCMA 的 CD3 双特异性和 ADC 模式的临床前疗效和安全性比较。
Mol Cancer Ther. 2019 Nov;18(11):2008-2020. doi: 10.1158/1535-7163.MCT-19-0007. Epub 2019 Aug 21.
3
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.认识到双特异性抗体治疗多发性骨髓瘤试验中的感染风险。
J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. Epub 2023 Jan 30.
4
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.用AMG 424靶向多发性骨髓瘤，AMG 424是一种新型抗CD38/CD3双特异性T细胞招募抗体，针对细胞毒性和细胞因子释放进行了优化。
Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752. Epub 2019 Mar 27.
5
Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.抗体药物偶联物和双特异性 T 细胞衔接器治疗多发性骨髓瘤新时代的曙光：文献系统评价。
Ann Hematol. 2021 Sep;100(9):2155-2172. doi: 10.1007/s00277-021-04599-5. Epub 2021 Jul 27.
6
Antibody treatment in multiple myeloma.多发性骨髓瘤的抗体治疗。
Clin Adv Hematol Oncol. 2021 Mar;19(3):166-174.
7
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.嵌合抗原受体 T 细胞和双特异性抗体治疗多发性骨髓瘤期间感染预防的建议。
Br J Haematol. 2023 Dec;203(5):736-746. doi: 10.1111/bjh.18909. Epub 2023 Jun 7.
8
Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma.双特异性抗体疗法治疗复发难治性多发性骨髓瘤时体液免疫缺陷的动力学
JAMA Netw Open. 2022 Oct 3;5(10):e2238961. doi: 10.1001/jamanetworkopen.2022.38961.
9
Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen.接受靶向B细胞成熟抗原的双特异性T细胞衔接器治疗的多发性骨髓瘤患者的持续性病毒感染
Haematologica. 2023 Nov 1;108(11):3186-3190. doi: 10.3324/haematol.2023.283003.
10
Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study.多发性骨髓瘤中抗B细胞成熟抗原双特异性单克隆抗体感染报告风险增加：一项全球药物警戒研究。
Am J Hematol. 2023 Dec;98(12):E349-E353. doi: 10.1002/ajh.27071. Epub 2023 Aug 30.
引用本文的文献
1
Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies.接受双特异性抗体治疗的多发性骨髓瘤患者感染并发症的发生率及特征
J Korean Med Sci. 2025 May 26;40(20):e86. doi: 10.3346/jkms.2025.40.e86.
2
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
3
Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review.嵌合抗原受体T细胞疗法和双特异性抗体后的疱疹病毒感染：综述
Viruses. 2025 Jan 18;17(1):133. doi: 10.3390/v17010133.
4
Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.T细胞重定向疗法有效使用的建议：一份加拿大共识声明。
Front Oncol. 2024 Nov 26;14:1446995. doi: 10.3389/fonc.2024.1446995. eCollection 2024.
5
Targeting GPRC5D for multiple myeloma therapy.针对多发性骨髓瘤的治疗靶点 GPRC5D。
J Hematol Oncol. 2024 Sep 28;17(1):88. doi: 10.1186/s13045-024-01611-z.
6
Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management.免疫球蛋白替代疗法：对多发性骨髓瘤管理的见解
Cancers (Basel). 2024 Sep 18;16(18):3190. doi: 10.3390/cancers16183190.
7
Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review.靶向B细胞成熟抗原用于复发/难治性多发性骨髓瘤患者的治疗与监测：综述
Ther Adv Hematol. 2024 Sep 14;15:20406207241275797. doi: 10.1177/20406207241275797. eCollection 2024.
8
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.多发性骨髓瘤的挑战性治疗方法：从疾病诊断与监测到并发症管理
Cancers (Basel). 2024 Jun 19;16(12):2263. doi: 10.3390/cancers16122263.
9
Beyond BCMA: newer immune targets in myeloma.超越 BCMA：多发性骨髓瘤的新免疫靶点。
Blood Adv. 2024 Aug 27;8(16):4433-4446. doi: 10.1182/bloodadvances.2023010856.
10
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.向前迈进：癌症治疗中重定向T细胞的双特异性抗体
Acta Pharm Sin B. 2024 Jun;14(6):2361-2377. doi: 10.1016/j.apsb.2024.03.027. Epub 2024 Mar 24.
本文引用的文献
1
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.抗 BCMA 双特异性抗体治疗多发性骨髓瘤患者中，使用 IVIg 与严重感染风险降低 10 倍相关。
Blood Cancer Discov. 2023 Nov 1;4(6):440-451. doi: 10.1158/2643-3230.BCD-23-0049.
2
Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma.双特异性抗体疗法治疗复发难治性多发性骨髓瘤时体液免疫缺陷的动力学
JAMA Netw Open. 2022 Oct 3;5(10):e2238961. doi: 10.1001/jamanetworkopen.2022.38961.
3
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.用于多发性骨髓瘤的 T 细胞重定向双特异性抗体：不断变化的治疗格局中的新兴治疗策略。
Leuk Lymphoma. 2022 Dec;63(13):3032-3043. doi: 10.1080/10428194.2022.2113532. Epub 2022 Sep 5.
4
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.ABBV-383 是一种 B 细胞成熟抗原 × CD3 双特异性 T 细胞重定向抗体，在复发/难治性多发性骨髓瘤患者中开展的 I 期首次人体研究。
J Clin Oncol. 2022 Nov 1;40(31):3576-3586. doi: 10.1200/JCO.22.01504. Epub 2022 Aug 27.
5
Bispecific Antibodies in Multiple Myeloma: Present and Future.双特异性抗体在多发性骨髓瘤中的应用：现状与未来。
Blood Cancer Discov. 2021 Aug 17;2(5):423-433. doi: 10.1158/2643-3230.BCD-21-0028. eCollection 2021 Sep.
6
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.新型疗法治疗多发性骨髓瘤患者的感染流行病学和风险。
Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):444-450.e3. doi: 10.1016/j.clml.2021.02.002. Epub 2021 Feb 18.
7
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study.新型疗法治疗多发性骨髓瘤患者的侵袭性真菌病发病率较低：一项多中心队列研究的结果。
Mycoses. 2021 Jan;64(1):30-34. doi: 10.1111/myc.13178. Epub 2020 Sep 17.
8
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.抗 B 细胞成熟抗原双特异性 T 细胞衔接分子 AMG 420 诱导多发性骨髓瘤产生应答。
J Clin Oncol. 2020 Mar 10;38(8):775-783. doi: 10.1200/JCO.19.02657. Epub 2020 Jan 2.
9
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
10
Infectious and immunological sequelae of daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的感染性和免疫性后遗症
Br J Haematol. 2019 Apr;185(1):187-189. doi: 10.1111/bjh.15433. Epub 2018 Jul 5.
Zotero 插件